Novartis Q4 Results

↓ ↑ Content Click below to navigate through the document Cosentyx® - IL-17A inhibitor Company overview Financial review Conclusions NCT05767034 REPLENISH (CAIN457C22301) Polymyalgia rheumatica Indication Phase Patients 360 Phase 3 Proportion of participants achieving sustained remission Cosentyx® - IL-17A inhibitor NCT04930094 GCAPTAIN (CAIN457R12301) Indication Giant cell arteritis Phase 3 Number of participants with sustained remission Phase Patients 348 Primary Outcome Intervention Arm 1 Experimental: Secukinumab 300 mg, randomized in 1:1:1 ratio every 4 weeks Arm 2 Experimental: Secukinumab 150 mg, randomized in 1:1:1 ratio every 4 weeks Arm 3 Placebo: randomized in 1:1:1 ratio every 4 weeks Target Patients Readout Milestone(s) Adult patients with PMR who have recently relapsed 2025 Publication TBD Measures Arms Intervention Target Patients Readout Milestone(s) Publication Experimental: Secukinumab 300 mg Placebo Comparator: Placebo Patients with Giant Cell Arteritis (GCA) Primary 2025 Final 2026 TBD Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Cardiovascular, Renal and Metabolic > Immunology Neuroscience Oncology Other Global Health Abbreviations Primary Outcome Measures Arms References □ NOVARTIS Reimagining Medicine | Novartis Q4 Results | January 31, 2024 57

View entire presentation